Loading...

Sarepta Therapeutics

DB:AB3A
Snowflake Description

Exceptional growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AB3A
DB
$9B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • Sarepta Therapeutics has significant price volatility in the past 3 months.
AB3A Share Price and Events
7 Day Returns
-3%
DB:AB3A
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
64.4%
DB:AB3A
-7.9%
DE Biotechs
-7.2%
DE Market
AB3A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sarepta Therapeutics (AB3A) -3% -5.1% 1.9% 64.4% 513.3% 286.4%
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • AB3A outperformed the Biotechs industry which returned -7.9% over the past year.
  • AB3A outperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
AB3A
Industry
5yr Volatility vs Market

Value

 Is Sarepta Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sarepta Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sarepta Therapeutics.

DB:AB3A Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 21 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:AB3A
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (4.81%))
1.343
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.34
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.343 * 5.96%)
8.23%

Discounted Cash Flow Calculation for DB:AB3A using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sarepta Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:AB3A DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.23%)
2019 -327.71 Analyst x6 -302.79
2020 -168.44 Analyst x6 -143.80
2021 154.37 Analyst x3 121.76
2022 1,122.40 Analyst x2 818.01
2023 1,382.07 Analyst x3 930.67
2024 1,583.76 Est @ 14.59% 985.39
2025 1,746.63 Est @ 10.28% 1,004.09
2026 1,873.56 Est @ 7.27% 995.16
2027 1,970.14 Est @ 5.16% 966.89
2028 2,042.59 Est @ 3.68% 926.22
Present value of next 10 years cash flows $6,301.60
DB:AB3A DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $2,042.59 × (1 + 0.23%) ÷ (8.23% – 0.23%)
$25,584.91
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $25,584.91 ÷ (1 + 8.23%)10
$11,601.56
DB:AB3A Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $6,301.60 + $11,601.56
$17,903.17
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $17,903.17 / 73.68
$243
DB:AB3A Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:AB3A represents 0.89329x of NasdaqGS:SRPT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89329x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 243.00 x 0.89329
€217.07
Value per share (EUR) From above. €217.07
Current discount Discount to share price of €106.06
= -1 x (€106.06 - €217.07) / €217.07
51.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Sarepta Therapeutics is available for.
Intrinsic value
>50%
Share price is €106.06 vs Future cash flow value of €217.07
Current Discount Checks
For Sarepta Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Sarepta Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Sarepta Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sarepta Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sarepta Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AB3A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-5.46
NasdaqGS:SRPT Share Price ** NasdaqGS (2019-04-17) in USD $118.73
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sarepta Therapeutics.

DB:AB3A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SRPT Share Price ÷ EPS (both in USD)

= 118.73 ÷ -5.46

-21.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sarepta Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Sarepta Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sarepta Therapeutics's expected growth come at a high price?
Raw Data
DB:AB3A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -21.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts
54.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sarepta Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sarepta Therapeutics's assets?
Raw Data
DB:AB3A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $14.52
NasdaqGS:SRPT Share Price * NasdaqGS (2019-04-17) in USD $118.73
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:AB3A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SRPT Share Price ÷ Book Value per Share (both in USD)

= 118.73 ÷ 14.52

8.17x

* Primary Listing of Sarepta Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sarepta Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Sarepta Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sarepta Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sarepta Therapeutics expected to perform in the next 1 to 3 years based on estimates from 21 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
54.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sarepta Therapeutics expected to grow at an attractive rate?
  • Sarepta Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Sarepta Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Sarepta Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AB3A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AB3A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts 54.4%
DB:AB3A Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 21 Analysts 37.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AB3A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AB3A Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 2,605 2,574 1,064 8
2022-12-31 1,788 1,688 1,340 9
2021-12-31 1,117 333 252 14
2020-12-31 608 -58 -165 18
2019-12-31 394 -262 -332 21
DB:AB3A Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 301 -389 -362
2018-09-30 274 -297 -245
2018-06-30 241 -242 -216
2018-03-31 203 -210 -170
2017-12-31 155 -232 -51
2017-09-30 103 -282 -115
2017-06-30 57 -285 -124
2017-03-31 22 -243 -123
2016-12-31 5 -246 -267
2016-09-30 1 -196 -243
2016-06-30 1 -182 -239
2016-03-31 1 -167 -218

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sarepta Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Sarepta Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AB3A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below

All data from Sarepta Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AB3A Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 22.27 48.20 6.89 6.00
2022-12-31 11.17 33.11 -4.29 8.00
2021-12-31 2.55 15.13 -4.13 12.00
2020-12-31 -2.78 0.67 -8.33 17.00
2019-12-31 -4.93 -2.77 -8.22 19.00
DB:AB3A Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -5.46
2018-09-30 -3.77
2018-06-30 -3.39
2018-03-31 -2.78
2017-12-31 -0.86
2017-09-30 -2.04
2017-06-30 -2.33
2017-03-31 -2.42
2016-12-31 -5.49
2016-09-30 -5.26
2016-06-30 -5.35
2016-03-31 -5.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Sarepta Therapeutics is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Sarepta Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sarepta Therapeutics has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sarepta Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sarepta Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sarepta Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sarepta Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sarepta Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sarepta Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sarepta Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AB3A Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 301.03 -361.92 209.98
2018-09-30 273.90 -245.02 177.74
2018-06-30 241.36 -216.36 152.73
2018-03-31 202.85 -170.14 133.44
2017-12-31 154.58 -50.69 116.31
2017-09-30 102.73 -115.14 105.36
2017-06-30 56.77 -124.15 99.02
2017-03-31 21.76 -123.41 86.57
2016-12-31 5.42 -267.27 81.20
2016-09-30 1.25 -243.49 84.50
2016-06-30 1.25 -238.69 77.90
2016-03-31 1.25 -218.24 73.30
2015-12-31 1.25 -220.03 65.86
2015-09-30 0.03 -199.77 55.45
2015-06-30 1.09 -177.05 53.24
2015-03-31 3.67 -169.08 52.42
2014-12-31 9.76 -135.79 49.32
2014-09-30 12.36 -100.19 45.45
2014-06-30 15.47 -113.00 40.58
2014-03-31 15.83 -98.17 35.62
2013-12-31 14.22 -111.99 31.59
2013-09-30 18.93 -165.23 25.96
2013-06-30 22.34 -172.76 21.52
2013-03-31 30.59 -145.67 17.18
2012-12-31 37.33 -121.29 14.51
2012-09-30 43.58 -60.63 13.05
2012-06-30 43.53 -15.10 12.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sarepta Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sarepta Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sarepta Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sarepta Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sarepta Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sarepta Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sarepta Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sarepta Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sarepta Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sarepta Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sarepta Therapeutics Company Filings, last reported 3 months ago.

DB:AB3A Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,032.28 420.55 1,173.91
2018-09-30 639.85 415.45 792.86
2018-06-30 699.05 439.44 949.14
2018-03-31 776.76 430.81 1,048.99
2017-12-31 789.22 431.05 1,079.06
2017-09-30 697.16 31.28 617.63
2017-06-30 377.77 11.22 300.95
2017-03-31 429.14 13.69 390.31
2016-12-31 336.69 16.15 317.85
2016-09-30 408.62 18.60 395.14
2016-06-30 121.46 20.22 123.22
2016-03-31 138.96 20.98 129.16
2015-12-31 190.35 23.40 192.49
2015-09-30 123.24 23.29 99.91
2015-06-30 165.38 25.66 156.89
2015-03-31 200.76 6.38 166.22
2014-12-31 247.65 6.33 210.34
2014-09-30 286.20 6.28 236.02
2014-06-30 299.92 1.62 279.54
2014-03-31 228.96 1.65 225.19
2013-12-31 247.19 1.67 256.97
2013-09-30 246.98 1.69 273.64
2013-06-30 88.82 1.71 156.19
2013-03-31 87.28 1.74 167.92
2012-12-31 123.68 1.76 187.66
2012-09-30 -4.57 1.78 37.99
2012-06-30 22.50 1.80 24.49
  • Sarepta Therapeutics's level of debt (40.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.7% vs 40.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sarepta Therapeutics has sufficient cash runway for 2.6 years based on current free cash flow.
  • Sarepta Therapeutics has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 29% each year.
X
Financial health checks
We assess Sarepta Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sarepta Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sarepta Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Sarepta Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sarepta Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sarepta Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AB3A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AB3A Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sarepta Therapeutics has not reported any payouts.
  • Unable to verify if Sarepta Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sarepta Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sarepta Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Sarepta Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Sarepta Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sarepta Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sarepta Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sarepta Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Doug Ingram
COMPENSATION $56,866,241
AGE 55
TENURE AS CEO 1.8 years
CEO Bio

Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 28, 2017. Mr. Ingram serves as Special Advisor on the executive leadership team at Actavis. Mr. Ingram served as the Chief Executive Officer and President at Chase Pharmaceuticals Corporation, Inc. since December 2, 2015. Mr. Ingram served as the President of Allergan Inc. from July 2013 to 2015. He served as the President of Europe, Africa, Middle East and Executive Vice President from August 1, 2010 to June 24, 2013. Mr. Ingram served as the Chief Administrative Officer of Allergan Inc., from October 2006 to August 1, 2010 and Chief Ethics Officer from July 2001 to August 1, 2010, Executive Vice President from October 2003 to August 1, 2010 and its General Counsel January 2001 to June 2009. He was Secretary at Allergan Inc., from October 2003 to August 1, 2010. He served as the Corporate Vice President of Allergan Inc. since July 2001. Mr. Ingram served as General Counsel and Secretary of Allergan Specialty Therapeutics Inc. since October 1998. He served as Allergan's General Secretary from July 2001 to July 2010. He served as Allergan's Assistant Secretary since November 1998. He served as Allergan Inc.'s Associate General Counsel since August 1998, Assistant General Counsel since January 1998 and Senior Attorney and Chief Litigation Counsel of Allergan since March 1996, when he first joined Allergan Inc. Mr. Ingram has more than two decades of executive leadership experience in the life sciences. He was responsible for building and leading numerous aspects of the global organization including Regulatory Affairs and Pharmacovigilance, Legal Affairs, Information Technology, Public Relations and External Communication, Human Resources, Audit and Compliance. He served as an Attorney with the law firm of Gibson, Dunn & Crutcher LLP from August 1988 to March 1996. He served as Vice Chairman and Director of Nemus Bioscience Inc. since June 1, 2015 until January 18, 2018. He has been a Director at Sarepta Therapeutics, Inc. since June 28, 2017. He served as a Director of Endo International plc since May 5, 2016. Mr. Ingram has been a Director of Volcom Australia Pty Ltd. since June 2005 and served as Director of Pacific Mutual Holding Company since May 1, 2015 until May 2018. He served as an Independent Director of Volcom, Inc., from June 2005 to June 17, 2011 and also served as its Lead Independent Director from June 2008 to June 17, 2011. He serves as the Director of Pacific Life insurance Company. He has been a Director at Chase Pharmaceuticals Corporation, Inc. since December 2, 2015. He served as a Trustee of Suburban Hospital, Inc. He served as a Director of ECC Capital Corp., from January 2005 to March 1, 2007. He serves on the Board of United Cerebral Palsy of Orange County. Mr. Ingram received a BS degree in 1985 from Arizona State University. He received his Juries Doctorate from University of Arizona in 1988.

CEO Compensation
  • Insufficient data for Doug to compare compensation growth.
  • Doug's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Sarepta Therapeutics management team in years:

1.8
Average Tenure
53
Average Age
  • The average tenure for the Sarepta Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Doug Ingram

TITLE
President
COMPENSATION
$57M
AGE
55
TENURE
1.8 yrs

Sandy Mahatme

TITLE
Executive VP
COMPENSATION
$2M
AGE
53
TENURE
6.4 yrs

Ty Howton

TITLE
Executive VP
COMPENSATION
$2M
AGE
46
TENURE
6.4 yrs

Alexander Cumbo

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$2M
AGE
47
TENURE
2.5 yrs

Ed Kaye

TITLE
COMPENSATION
$5M
AGE
69
TENURE
1.8 yrs

Ian Estepan

TITLE
Senior VP of Corporate Affairs & Chief of Staff
TENURE
1.3 yrs

Gilmore O'Neill

TITLE
Executive VP of R&D and Chief Medical Officer
TENURE
0.8 yrs

Louise Rodino-Klapac

TITLE
Senior Vice President of Gene Therapy
TENURE
0.1 yrs

Gary Charbonneau

TITLE
Senior VP of Global Regulatory Affairs
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Sarepta Therapeutics board of directors in years:

3.7
Average Tenure
62.5
Average Age
  • The tenure for the Sarepta Therapeutics board of directors is about average.
Board of Directors

M. Behrens

TITLE
Chairwoman
COMPENSATION
$361K
AGE
66
TENURE
4 yrs

Doug Ingram

TITLE
President
COMPENSATION
$57M
AGE
55
TENURE
1.8 yrs

Hans Wigzell

TITLE
Chairman of Corporate Strategy Board & Non-Employee Director
COMPENSATION
$308K
AGE
80

Claude Nicaise

TITLE
Non-Employee Director
COMPENSATION
$300K
AGE
65
TENURE
3.8 yrs

Rick Barry

TITLE
Non-Employee Director
COMPENSATION
$327K
AGE
59
TENURE
3.8 yrs

Louis Kunkel

TITLE
Member of Strategic & Scientific Advisory Board
TENURE
3.7 yrs

Bev Davidson

TITLE
Member of Strategic & Scientific Advisory Board
TENURE
3.7 yrs

Kenneth Fischbeck

TITLE
Member of Strategic & Scientific Advisory Board
TENURE
2.1 yrs

Matthew Wood

TITLE
Member of Strategic & Scientific Advisory Board
TENURE
2.1 yrs

Mike Bonney

TITLE
Director
COMPENSATION
$416K
AGE
60
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
30. Oct 18 Buy Douglas Ingram Individual 30. Oct 18 30. Oct 18 16,695 €106.44 €1,768,888
16. Aug 18 Buy Douglas Ingram Individual 15. Aug 18 15. Aug 18 16,000 €110.64 €1,770,320
X
Management checks
We assess Sarepta Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sarepta Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company’s pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children’s Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit’s utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Details
Name: Sarepta Therapeutics, Inc.
AB3A
Exchange: DB
Founded: 1980
$7,740,713,978
73,676,054
Website: http://www.sarepta.com
Address: Sarepta Therapeutics, Inc.
215 First Street,
Suite 415,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SRPT Common Stock Nasdaq Global Select US USD 04. Jun 1997
DB AB3A Common Stock Deutsche Boerse AG DE EUR 04. Jun 1997
LSE 0L35 Common Stock London Stock Exchange GB USD 04. Jun 1997
Number of employees
Current staff
Staff numbers
499
Sarepta Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 22:21
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.